Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L32 pseudogene 21 (RPL32P21) is a human pseudogene that is related to the ribosomal protein L32 gene family[7][8][2]. Unlike functional protein-coding genes, pseudogenes like RPL32P21 are generally considered nonfunctional DNA segments that arise from duplication or retrotransposition events and usually lack protein-coding capacity. There is no evidence to support a role for RPL32P21 as a therapeutic target, as it does not encode an active ribosomal protein or demonstrate direct biological, disease, or pharmacological functions. Its main relevance is as a genomic element and as a member of the broader ribosomal protein L32 gene family, which does contain functional genes such as RPL32. There are no known drugs, biomarkers, or clinical safety considerations directly associated with this pseudogene[7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L32 pseudogene 21 (RPL32P21).